Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals

被引：0
|
作者：
Austin Lammers
Ruibin Wang
Jeremy Cetnar
Vinay Prasad
机构：
[1] Oregon Health & Science University,Division of Hematology Oncology, Knight Cancer Institute
[2] Johns Hopkins Bloomberg School of Public Health,Department of Epidemiology
[3] Oregon Health & Science University,Department of Public Health and Preventive Medicine
[4] Oregon Health & Science University,Center for Health Care Ethics
来源：
Blood Cancer Journal | / 7卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs
    Kim, Chul
    Prasad, Vinay
    MAYO CLINIC PROCEEDINGS, 2016, 91 (06) : 713 - 725
  • [42] Disparity of race reporting in US Food and Drug Administration drug approvals for urinary system cancers from 2006 to 2021
    Glover, Michael
    Hui, Gavin
    Chiang, Ryan
    Savage, Philip
    Krell, Jonathan
    Julve, Maximilian
    Grivas, Petros
    Lythgoe, Mark
    Khaki, Ali Raza
    BJU INTERNATIONAL, 2022, 129 (02) : 168 - 170
  • [43] National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study
    Etan, Tal
    Amir, Eitan
    Tibau, Adriane
    Yerushalmi, Rinat
    Moore, Assaf
    Shepshelovich, Daniel
    Goldvaser, Hadar
    CANCER TREATMENT REVIEWS, 2020, 91
  • [44] Accelerated approval of Iressa from FDA news releases (FDA US Food and Drug Administration)
    Shimada, Y
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (07) : 369 - 369
  • [45] US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials A Systematic Review and Meta-analysis
    Razavi, Marianne
    Glasziou, Paul
    Klocksieben, Farina A.
    Ioannidis, John P. A.
    Chalmers, Iain
    Djulbegovic, Benjamin
    JAMA NETWORK OPEN, 2019, 2 (09)
  • [46] Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada
    Lythgoe, Mark P.
    Middleton, Paul
    JAMA NETWORK OPEN, 2021, 4 (06)
  • [47] Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US
    Ermer, Theresa
    Canavan, Maureen E.
    Maduka, Richard C.
    Li, Andrew X.
    Salazar, Michelle C.
    Kaminski, Michael F.
    Pichert, Matthew D.
    Zhan, Peter L.
    Mase, Vincent
    Kluger, Harriet
    Boffa, Daniel J.
    JAMA NETWORK OPEN, 2022, 5 (06) : E2219535
  • [48] Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration
    Molto, Consolacion
    Hwang, Thomas J.
    Borrell, Maria
    Andres, Marta
    Gich, Ignasi
    Barnadas, Agusti
    Amir, Eitan
    Kesselheim, Aaron S.
    Tibau, Ariadna
    CANCER, 2020, 126 (19) : 4390 - 4399
  • [49] RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
    Cherny, Nathan I.
    Dafni, Urani
    Bogaerts, Jan
    Latino, Nicola J.
    Pentheroudakis, George
    Douillard, Jean-Yves
    Tabernero, Josep
    Zielinski, Christoph
    Piccart, Martine J.
    de Vries, Elisabeth G. E.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (10):
  • [50] A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration
    He, Qian
    Li, Qiu
    Lv, Fanzhen
    Kaitin, Kenneth I.
    Shao, Liming
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2021, 55 (04) : 676 - 684
12345